Texas A&M Researchers Reverse Brain Aging via Intranasal EV Therapy

Researchers at the Texas A&M University Naresh K. Vashisht College of Medicine have developed a nasal spray therapy capable of reducing brain inflammation and restoring cognitive function in aging brains. The study, published in the Journal of Extracellular Vesicles, demonstrates that a two-dose regimen can reverse "neuroinflammaging," restore cellular energy production, and improve memory retention for several months.

Reversing Neuroinflammaging with Intranasal Delivery

Chronic inflammation in the brain's memory centers, termed "neuroinflammaging," is a primary driver of cognitive decline and an increased risk for Alzheimer's disease. This research proves that this inflammatory state is reversible without the need for invasive brain surgery.

By using a nasal spray, the therapy bypasses the blood-brain barrier to deliver treatment directly into brain tissue. This non-invasive approach allows for the direct targeting of the brain's resident immune cells, providing a safer and more efficient alternative to traditional medication or surgical interventions.

Mechanism of Action: Extracellular Vesicles and microRNAs

The therapy utilizes millions of extracellular vesicles (EVs)—microscopic biological parcels—to transport genetic cargo known as microRNAs into the brain.

Genetic Regulation and Inflammation Suppression

MicroRNAs act as master regulators that modulate gene and signaling pathways. Once absorbed, these microRNAs specifically suppress two key drivers of chronic inflammation in the aging brain:

• NLRP3 inflammasome: A protein complex responsible for triggering inflammatory responses.
• cGAS–STING signaling pathways: Pathways known to drive persistent inflammation in aged neural tissue.

Mitochondrial Restoration

Beyond suppressing inflammation, the therapy recharges neuronal mitochondria, the cellular power plants of the brain. By reducing oxidative stress and reactivating these mitochondria, the treatment restores the neurons' ability to process and store information, effectively "giving neurons their spark back."

Observed Outcomes and Clinical Implications

Behavioral tests on models treated with the nasal spray showed significant improvements in memory and environmental awareness, specifically in recognizing familiar objects and detecting new objects or changes in their surroundings.

Key findings from the study include:

• Rapid and Sustained Effect: Improvements occurred within weeks and lasted for several months after only two doses.
• Universal Efficacy: The treatment outcomes were consistent across both sexes, a rarity in biomedical research.
• Broad Potential: While focused on aging, the researchers suggest the approach could potentially help stroke survivors rebuild lost brain function.

Research Context and Future Outlook

Supported by the National Institute on Aging (NIA), the team led by Dr. Ashok Shetty has filed a U.S. patent for the therapy. This development arrives as dementia cases in the United States are projected to double by 2060, increasing from approximately 514,000 in 2020 to 1 million.

Source Reference: Intranasal Human NSC‑Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS‑STING Signalling, in Aged Hippocampus, Journal of Extracellular Vesicles 15(2): e70232 (2026). DOI: 10.1002/jev2.70232.